Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 14.07.2021 | 08:36

Aladdin Healthcare Technologies with new research findings on COVID-19 diagnosis

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Scientific publication
14.07.2021 / 08:36
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies with new research findings on COVID-19 diagnosis

BERLIN/LONDON, July 14, 2021 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, is one of the co-authors of a high-impact review on the state of the art in research on machine learning applied to the detection and prognostication of COVID-19.

The review has been published on Nature Machine Intelligence, a prestigious scientific monthly journal based in London, with a focus on topics like Artificial Intelligence, Machine Learning and Robotics. Aladdin together with major representatives of the international academic world made its contribution to the research advancement in a field that is as current as it is crucial given the persistence of the coronavirus pandemic.

Machine learning methods can be used for rapid and accurate detection of COVID-19 at a very early stage from standard chest radiographs (CXR) and chest computed tomography (CT) images. They can become a complement of standard PCR tests or even a substitute in countries where no PCR tests are available. That's why it is so important to continue and develop research in this field.

The systematic review at which the Aladdin team took part started with a detailed screening of more than 2,000 studies published in 2020 and focused only on those papers with sufficiently documented methodologies. The analysis led to the conclusion that none of the identified models are of potential clinical use and gave recommendations to aim for a higher-quality model development and well-documented manuscripts. This review represents a stepping stone toward a new standard of big data sharing at an international level, including multimodal data such as imaging, by using a new proprietary AI platform on which Aladdin is currently working. The aim is to collaborate with big players of the international healthcare industry and to provide a new method to diagnose cardiovascular and lung diseases which are serious conditions associated with COVID-19.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: "With our contribution to this analysis, we are putting our extensive effort together with the international community to tackle the COVID-19 pandemic using machine learning. Our aim is to overcome the weaknesses of current studies and find concrete innovative solutions for the clinical use of new AI algorithms."

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link:

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330

14.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Interview im Fokus

„Eine Investition in Mutares lohnt sich“

Mutares ist ein europaweit führender Private-Equity-Investor, der sich auf Sondersituationen wie Abspaltungen von großen Konzernen oder Turnaround- und Nachfolgesituationen spezialisiert hat. Ziel ist es, mit den Investments einen Return auf das eingesetzte Kapital von 7 bis 10 zu erzielen. Mit der jüngsten Mittelfristprognose hat der Münchner Finanzinvestor auf Basis von 5 Mrd. Euro Konzernumsatz eine Nettorendite für die börsennotierte Holding von 1,8 bis 2,2 % in Aussicht gestellt. In der Mitte der Zielspanne wird somit ein Nettogewinn von circa 100 Mio. Euro anvisiert. Hauck & Aufhäuser hat in der jüngsten Analyse ein Buy-Rating mit Kursziel für Mutares von 37,50 Euro ausgegeben.

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“


Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

FORTEC Elektronik Aktiengesellschaft

Original-Research: FORTEC Elektronik AG (von Montega AG): Kaufen

23. September 2021